These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14628758)

  • 1. Topical therapies for glaucoma and ocular hypertension: an update on current practice.
    Rouland JF
    Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S1-4. PubMed ID: 14628758
    [No Abstract]   [Full Text] [Related]  

  • 2. A myth of ophthalmic beta-blockers therapy.
    Kittisupamongkol W
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1721; author reply 1723. PubMed ID: 19693528
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient satisfaction with topical ocular hypotensives.
    Kerr NM; Patel HY; Chew SS; Ali NQ; Eady EK; Danesh-Meyer HV
    Clin Exp Ophthalmol; 2013; 41(1):27-35. PubMed ID: 22594958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction: new insights on enhancing adherence to topical glaucoma medications.
    Friedman DS
    Ophthalmology; 2009 Nov; 116(11 Suppl):S29. PubMed ID: 19837257
    [No Abstract]   [Full Text] [Related]  

  • 5. Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment.
    Romero-Díaz de León L; Morales-León JE; Ledesma-Gil J; Navas A
    Int Ophthalmol; 2016 Jun; 36(3):299-303. PubMed ID: 26272426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval.
    Duggan S
    Drugs; 2018 Dec; 78(18):1925-1929. PubMed ID: 30465134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to glaucoma drug delivery.
    Ghate D; Edelhauser HF
    J Glaucoma; 2008 Mar; 17(2):147-56. PubMed ID: 18344762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.
    Skaat A; Jasien JV; Ritch R
    J Glaucoma; 2016 Sep; 25(9):e807-14. PubMed ID: 27552517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Topical prostaglandins influence over cornea--preliminary report].
    Wierzbowska J; Stankiewicz A
    Klin Oczna; 2006; 108(10-12):479-81. PubMed ID: 17455732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and new pharmacotherapeutic approaches for glaucoma.
    Shalaby WS; Shankar V; Razeghinejad R; Katz LJ
    Expert Opin Pharmacother; 2020 Nov; 21(16):2027-2040. PubMed ID: 32717157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
    Hermann MM; Papaconstantinou D; Muether PS; Georgopoulos G; Diestelhorst M
    Acta Ophthalmol; 2011 Jun; 89(4):e300-5. PubMed ID: 21106046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An objective evaluation of eyedrop instillation in patients with glaucoma.
    Stone JL; Robin AL; Novack GD; Covert DW; Cagle GD
    Arch Ophthalmol; 2009 Jun; 127(6):732-6. PubMed ID: 19506189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy.
    Soltau JB
    J Glaucoma; 2004 Aug; 13(4):348; author reply 348. PubMed ID: 15226666
    [No Abstract]   [Full Text] [Related]  

  • 14. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern alchemy: fixed combinations of glaucoma drugs.
    Katz LJ
    Am J Ophthalmol; 2005 Jul; 140(1):125-6. PubMed ID: 16038653
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of disease severity on quality of eye-drop administration in patients with glaucoma or ocular hypertension.
    Aptel F; Masset H; Burillon C; Robin A; Denis P
    Br J Ophthalmol; 2009 May; 93(5):700-1. PubMed ID: 19395633
    [No Abstract]   [Full Text] [Related]  

  • 17. Bimatoprost versus timolol and dorzolamide.
    Tressler CS
    Ophthalmology; 2005 Feb; 112(2):357-8; author reply 358-9. PubMed ID: 15691575
    [No Abstract]   [Full Text] [Related]  

  • 18. [The influence of ocular surface diseases in the management of glaucoma].
    Van Went C; Brasnu E; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Apr; 34(4):230-7. PubMed ID: 21439676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Timolol topical ophthalmic combination].
    Călugăru M; Călugăru D
    Oftalmologia; 2004; 48(1):5-14. PubMed ID: 15279411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.